Premium
Individualizing the Use of Medications in Children: Making Goldilocks Happy
Author(s) -
Leeder J S,
Brown J T,
Soden S E
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.130
Subject(s) - clinical pharmacology , goldilocks principle , dosing , medicine , pharmacokinetics , drug , pharmacology , drug development , drug response , clinical trial , pharmacogenomics , intensive care medicine , biology , astrobiology
To date, implementation of precision medicine for children has been limited. Extrapolation of adult experience streamlines pediatric drug development programs, and physiologically based pharmacokinetic models aid pediatric dose selection on a population basis. To achieve clinically viable individualization of drug therapy, genotype‐stratified pharmacokinetic studies can efficiently characterize the extremes of the dose–exposure relationship. Reducing variability in exposure through genotype‐based dosing may improve identification of genetic factors contributing to response, ultimately improving drug therapy for children. Clinical Pharmacology & Therapeutics (2014); 96 3, 304–306. advance online publication 23 July 2014. doi: 10.1038/clpt.2014.130